Jakavi 20 mg Tablet is an advanced oral medication containing Ruxolitinib, developed by Novartis, designed to manage and treat certain rare blood disorders, particularly myelofibrosis and polycythemia vera. As a Janus kinase (JAK) inhibitor, Jakavi works by targeting specific enzymes (JAK1 and JAK2) involved in the overproduction of blood cells and inflammatory processes. This targeted approach has transformed the management of myeloproliferative neoplasms, offering patients relief from debilitating symptoms, reducing spleen size, and improving their quality of life.
Key Product Details:
- Active Ingredient: Ruxolitinib 20 mg
- Form: Film-Coated Tablet
- Administration: Oral Use (Taken by mouth)
- Packaging: 56 Tablets per Box
- Manufacturer: Novartis Pharmaceuticals
Benefits of Jakavi 20 mg:
- Reduction in Spleen Size: Significantly reduces spleen enlargement in patients with myelofibrosis.
- Symptom Control: Provides relief from common symptoms such as fatigue, night sweats, itching (pruritus), bone pain, and unintentional weight loss.
- Polycythemia Vera Management: Helps control hematocrit levels in patients resistant to or intolerant of hydroxyurea, reducing the risk of thrombotic events.
- Improved Quality of Life: Enhances patients’ day-to-day well-being by alleviating disease-related symptoms.
- Targeted JAK Inhibition: Selectively inhibits JAK1 and JAK2 enzymes, addressing the underlying mechanism of myeloproliferative neoplasms.
Indications and Approved Uses:
- Myelofibrosis (MF): Primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in patients with splenomegaly or disease-related symptoms.
- Polycythemia Vera (PV): Treatment of patients resistant to or intolerant of hydroxyurea.
- Graft-Versus-Host Disease (GVHD): Emerging use in chronic GVHD following stem cell transplantation (consult your physician for off-label use).
How Does Jakavi (Ruxolitinib) Work?
Jakavi contains Ruxolitinib, a potent Janus kinase inhibitor (JAK1/JAK2 inhibitor). Myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, are driven by mutations in the JAK-STAT signaling pathway, causing excessive blood cell production and inflammation. Ruxolitinib works by blocking JAK1 and JAK2, normalizing blood cell production and reducing inflammation, leading to:
- Decreased cytokine levels
- Reduced spleen size
- Symptom relief
- Lower risk of blood clots in polycythemia vera patients
Dosage and Administration:
- Standard Dosage: Typically 10 mg to 25 mg twice daily, depending on platelet count, disease severity, and patient response.
- Adjustments: Dose adjustments are often required based on blood counts (e.g., hemoglobin, platelets). Regular monitoring is essential.
- Method of Intake: Taken orally, with or without food. Maintain consistent timing for optimal results.
Important Safety Information:
- Low Blood Cell Counts: Risk of anemia, thrombocytopenia, and neutropenia. Routine blood tests are required.
- Infections: Increased susceptibility to infections, including tuberculosis, hepatitis B reactivation, and herpes zoster.
- Liver and Kidney Impairment: Dose adjustment is necessary for patients with hepatic or renal dysfunction.
- Bleeding Risk: Patients with low platelet counts need close monitoring.
- Withdrawal Syndrome: Sudden discontinuation may lead to a return of symptoms or acute worsening; tapering may be recommended.
- Pregnancy and Breastfeeding: Consult a healthcare provider. Potential risks to the fetus; contraception is advised during and after treatment.
Storage Instructions:
- Temperature: Store at 25°C (77°F). Temporary storage between 15°C to 30°C (59°F to 86°F) is acceptable.
- Protect from Moisture: Keep tablets in their original blister pack until use.
Why Choose Jakavi 20 mg Tablet?
- Trusted Brand: Produced by Novartis, a global leader in oncology and hematology treatments.
- Proven Symptom Relief: Demonstrated efficacy in clinical trials, improving quality of life for patients with myelofibrosis and polycythemia vera.
- Comprehensive Disease Control: Reduces spleen size, manages hematocrit levels, and alleviates systemic symptoms.
- Targeted Therapy: JAK1/JAK2 inhibition provides precision treatment targeting the underlying pathway of myeloproliferative disorders.
Clinical Trial Highlights:
- COMFORT Trials (COMFORT-I & COMFORT-II): Patients with myelofibrosis treated with Jakavi experienced significant spleen size reduction and improved symptoms compared to placebo or best available therapy.
- RESPONSE Trial: Patients with polycythemia vera resistant to hydroxyurea showed better hematocrit control and spleen volume reduction with Ruxolitinib compared to standard therapy.
Buy Jakavi 20 mg Online:
Looking to buy Jakavi 20 mg Ruxolitinib tablets online? We offer genuine Novartis Jakavi with fast delivery and global shipping options. Take control of myelofibrosis and polycythemia vera with this cutting-edge JAK inhibitor therapy.
Değerlendirmeler
Henüz değerlendirme yapılmadı.